Compare TransMedics Group Inc (TMDX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Yum China Holdings Inc — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Yum China Holdings Inc trades at $43.07 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 5.1× TransMedics Group Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Yum China Holdings Inc for 77 Days on average.
| TMDX | YUMC | |
|---|---|---|
Market Cap | $2.74B | $14.11B |
Volume | 949,331 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $57.95 |
52-Week Low | $61.99 | $39.98 |
Typical Hold Time | 24 Days | 77 Days |
Enterprise Value | $3.13B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
YUMC trades at $42.99, up 5.76% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 73.68% analyst buy consensus highlight positive momentum. The company completed the Pizza Hut China brand acquisition and expanded its Burger Bar concept, signaling growth initiatives. Cash flow from operations remains robust at $1.47B for 2025, though net cash flow is negative due to financing activities.
The outlook is mixed: solid earnings growth and expansion potential support upside, but technical weakness and competitive pressures pose risks. Investors should weigh the attractive valuation (P/E 15.3) against near-term price volatility and market sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
